Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Ferric derisomaltose therapy and heart failure: implications and molecular insights

Iron is essential to the production of myocardial energy and proteins critical for cardiovascular function. Nearly 50% of patients with heart failure with reduced ejection fraction (HFrEF) meet current criteria for iron deficiency, and there has been considerable interest in intravenous repletion of iron stores as a therapeutic strategy to improve HFrEF outcomes. However, the data on intravenous iron therapy in HFrEF have been mixed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Iron therapy delivery in heart failure.

References

  1. Kalra, P. R. et al. Lancet https://doi.org/10.1016/S0140-6736(22)02083-9 (2022).

    Article  Google Scholar 

  2. von Haehling, S., Ebner, N., Evertz, R., Ponikowski, P. & Anker, S. D. JACC Heart Fail. 7, 36–46 (2019).

    Article  Google Scholar 

  3. Ponikowski, P. et al. Lancet 396, 1895–1904 (2020).

    Article  CAS  Google Scholar 

  4. McDonagh, T. A. et al. Eur. Heart J. 42, 3599–3726 (2021).

    Article  CAS  Google Scholar 

  5. Heidenreich, P. A. et al. Circulation 145, e895–e1032 (2022).

    Google Scholar 

  6. Sawicki, K. T. & Ardehali, H. Ann. Intern. Med. 175, HO2–HO3 (2022).

    Article  Google Scholar 

  7. Ghafourian, K., Shapiro, J. S., Goodman, L. & Ardehali, H. JACC Basic Transl. Sci. 5, 300–313 (2020).

    Article  Google Scholar 

  8. Masini, G. et al. J. Am. Coll. Cardiol. 79, 341–351 (2022).

    Article  CAS  Google Scholar 

  9. Petrak, J. et al. Biochim. Biophys. Acta Gen. Subj. 1863, 703–713 (2019).

    Article  CAS  Google Scholar 

  10. Melenovsky, V. et al. Eur. J. Heart Fail. 19, 522–530 (2017).

    Article  CAS  Google Scholar 

  11. Docherty, K. F. et al. Circulation 146, 980–994 (2022).

    Article  CAS  Google Scholar 

  12. Fang, X., Ardehali, H., Min, J. & Wang, F. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00735-4 (2022).

    Article  Google Scholar 

  13. Zoller, H. et al. Gut https://doi.org/10.1136/gutjnl-2022-327897 (2022).

    Article  Google Scholar 

  14. Sawicki, K. T. & Ardehali, H. Eur. Heart J. 43, 345–346 (2022).

    Article  Google Scholar 

  15. Sawicki, K. T. & Ardehali, H. Circulation 144, 253–255 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hossein Ardehali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sawicki, K.T., Ardehali, H. Ferric derisomaltose therapy and heart failure: implications and molecular insights. Nat Cardiovasc Res 2, 3–5 (2023). https://doi.org/10.1038/s44161-022-00202-w

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s44161-022-00202-w

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing